ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cellâs own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRQR
āļāļ·āđāļāļāļĢāļīāļĐāļąāļProQR Therapeutics NV
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 18, 2014
āļāļĩāļāļĩāđāļde Boer (Daniel Anton)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ166
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļSep 18
āļāļĩāđāļāļĒāļđāđZernikedreef 9
āđāļĄāļ·āļāļLEIDEN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻNetherlands
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ2333 CK
āđāļāļĢāļĻāļąāļāļāđ31881667000
āđāļ§āđāļāđāļāļāđhttps://www.proqr.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPRQR
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 18, 2014
āļāļĩāļāļĩāđāļde Boer (Daniel Anton)
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
Ms. Theresa M. Heggie
Non-Executive Director
Ms. Sarah Kiely
Vice President - Investor Relations & Corporate Affairs
Vice President - Investor Relations & Corporate Affairs
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
Dr. Dinko Valerio, Ph.D.
Non-Executive Director
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director